Lamivudine Structural Formula (Epivir Spl Graphic 01)
Epivir Tablet, Film Coated
Product Images NDC 49702-203
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Epivir (NDC 49702-203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Viiv Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1. Virologic Response Through Week 48, Epv20001ab (intent-to-treat (Epivir Spl Graphic 02)
This is a chart or graph displaying the proportions of subjects with HIV-1 RNA levels less than 400 copies/mL while on different treatments of Epivir. The Epivir treatments were either 150mg taken three times a day or 300mg taken once daily. The chart shows the results over a period of 22 weeks, with measurements taken at weeks 4, 8, 12, 16, 20, and 22.*
Epivir 150 mg 60 Count Label (Epivir Spl Graphic 03)
Epivir 300mg 30 Count Label (Epivir Spl Graphic 04)
This appears to be a product description of EPIVIR tablets containing 300mg of lamivudine, intended for therapeutic use. It provides information regarding the storage temperature range (10-30°C) and manufacturer details.*
Epivir Oral Solution 240ml Carton (Epivir Spl Graphic 05)
This is a medication with National Drug Code (NDC) 49702-205-48. It has a concentration of 10 mg/mL and is alcohol-free. The quantity provided is 240 mL.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
